Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydroxypropyl methylcellulose (HPMC, also known as hypromellose) combined with povidone is a multi-ingredient ophthalmic formulation primarily used as an artificial tear or ocular lubricant for the symptomatic treatment of dry eye disease. HPMC is a semi-synthetic, inert polymer that mimics natural tears by stabilizing and thickening the precorneal tear film, prolonging tear film breakup time, and providing lubrication to protect the corneal surface[1][2]. Povidone (polyvinylpyrrolidone) acts as a water-soluble polymer that enhances viscosity and helps retain moisture on the ocular surface[4][6]. The combination improves corneal hydration and may help maintain physiological corneal density in patients with dry eye syndrome[1]. Both components are considered pharmacologically inert in this context; their primary mechanism is physical protection and lubrication rather than direct pharmacological action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydroxypropyl methylcellulose + povidone.